Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU among others, is a second-generation lipoglycopeptide antibiotic medication. From Wikipedia
Results published in JAMA show the regimen achieved comparable day-70 outcomes with fewer catheter-related adverse events
